
## **Ulrike Muscha Steckelings**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4995683/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Targeting angiotensin type-2 receptors located on pressor neurons in the nucleus of the solitary tract to relieve hypertension in mice. Cardiovascular Research, 2022, 118, 883-896.	3.8	9
2	Angiotensin Receptors - Affinity and Beyond. Clinical Science, 2022, 136, 799-802.	4.3	2
3	C21 preserves endothelial function in the thoracic aorta from DIO mice: role for AT2, Mas and B2 receptors. Clinical Science, 2021, 135, 1145-1163.	4.3	8
4	The protective effect of Angiotensin AT2-receptor stimulation in Neuromyelitis optica spectrum disorder is independent of astrocyte-derived BDNF. Multiple Sclerosis and Related Disorders, 2021, 53, 103033.	2.0	1
5	AT2R stimulation with C21 prevents arterial stiffening and endothelial dysfunction in the abdominal aorta from mice fed a high-fat diet. Clinical Science, 2021, 135, 2763-2780.	4.3	8
6	Angiotensin AT2 receptor–induced interleukin-10 attenuates neuromyelitis optica spectrum disorder–like pathology. Multiple Sclerosis Journal, 2020, 26, 1187-1196.	3.0	9
7	The reninâ€angiotensin system in cutaneous hypertrophic scar and keloid formation. Experimental Dermatology, 2020, 29, 902-909.	2.9	31
8	The role of the reninâ€angiotensin system in skin physiology and pathophysiology. Experimental Dermatology, 2020, 29, 891-901.	2.9	27
9	The Renin-Angiotensin System in Hypertension, a Constantly Renewing Classic: Focus on the Angiotensin AT2-Receptor. Canadian Journal of Cardiology, 2020, 36, 683-693.	1.7	23
10	Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists. Clinical Science, 2020, 134, 2987-3006.	4.3	35
11	Antiâ€fibrotic mechanisms of angiotensin AT <sub>2</sub> â€receptor stimulation. Acta Physiologica, 2019, 227, e13280.	3.8	38
12	The renin-angiotensin system: going beyond the classical paradigms. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H958-H970.	3.2	218
13	Protective effects of the angiotensin II AT2 receptor agonist compound 21 in ischemic stroke: a nose-to-brain delivery approach. Clinical Science, 2018, 132, 581-593.	4.3	21
14	Identification of protein phosphatase involvement in the AT2 receptor-induced activation of endothelial nitric oxide synthase. Clinical Science, 2018, 132, 777-790.	4.3	35
15	Smallâ€molecule AT2 receptor agonists. Medicinal Research Reviews, 2018, 38, 602-624.	10.5	28
16	Chronic administration of the angiotensin type 2 receptor agonist C21 improves insulin sensitivity in C57BL/6 mice Physiological Reports, 2018, 6, e13824.	1.7	18
17	Neuroprotection via AT2 receptor agonists in ischemic stroke. Clinical Science, 2018, 132, 1055-1067.	4.3	34
18	The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury. Frontiers in Physiology, 2018, 9, 180.	2.8	53

#	Article	IF	CITATIONS
19	Protective Angiotensin Type 2 Receptors in the Brain and Hypertension. Current Hypertension Reports, 2017, 19, 46.	3.5	30
20	Evidence for Heterodimerization and Functional Interaction of the Angiotensin Type 2 Receptor and the Receptor MAS. Hypertension, 2017, 69, 1128-1135.	2.7	87
21	Angiotensin II Type 2 Receptor and Receptor Mas Are Colocalized and Functionally Interdependent in Obese Zucker Rat Kidney. Hypertension, 2017, 70, 831-838.	2.7	48
22	Centrally Mediated Cardiovascular Actions of the Angiotensin II Type 2 Receptor. Trends in Endocrinology and Metabolism, 2017, 28, 684-693.	7.1	30
23	The angiotensin type 2 receptor and the kidney. Current Opinion in Nephrology and Hypertension, 2017, 26, 36-42.	2.0	14
24	Post-stroke angiotensin II type 2 receptor activation provides long-term neuroprotection in aged rats. PLoS ONE, 2017, 12, e0180738.	2.5	19
25	Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice. Journal of Molecular Medicine, 2016, 94, 957-966.	3.9	39
26	The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis. Diabetologia, 2016, 59, 1778-1790.	6.3	38
27	OS 32-03 ANGIOTENSIN II TYPE 2 RECEPTOR AGONIST EXERTS SUSTAINED NEUROPROTECTIVE EFFECTS IN AGED RATS. Journal of Hypertension, 2016, 34, e390.	0.5	0
28	Compound 21, a selective agonist of angiotensin AT <sub>2</sub> receptors, prevents endothelial inflammation and leukocyte adhesion <i>in vitro</i> and <i>in vivo</i> . British Journal of Pharmacology, 2016, 173, 729-740.	5.4	51
29	Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders. Drugs, 2016, 76, 1-12.	10.9	34
30	Reporter mouse strain provides a novel look at angiotensin type-2 receptor distribution in the central nervous system. Brain Structure and Function, 2016, 221, 891-912.	2.3	89
31	Angiotensin type 2 receptors: blood pressure regulation and end organ damage. Current Opinion in Pharmacology, 2015, 21, 115-121.	3.5	70
32	Neuroprotective Mechanisms of the ACE2–Angiotensin-(1-7)–Mas Axis in Stroke. Current Hypertension Reports, 2015, 17, 3.	3.5	70
33	Angiotensin typeÂ2 receptor (AT2R) and receptor Mas: a complex liaison. Clinical Science, 2015, 128, 227-234.	4.3	89
34	AT2R Agonist, Compound 21, Is Reno-Protective Against Type 1 Diabetic Nephropathy. Hypertension, 2015, 65, 1073-1081.	2.7	61
35	Direct angiotensin typeÂ2 receptor (AT2R) stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice. Clinical Science, 2015, 128, 95-109.	4.3	43
36	Activation of intracellular angiotensin AT2 receptors induces rapid cell death in human uterine leiomyosarcoma cells. Clinical Science, 2015, 128, 567-578.	4.3	12

#	Article	IF	CITATIONS
37	The Angiotensin AT2 Receptor. , 2015, , 1-9.		7
38	Stimulation of the Angiotensin II AT2 Receptor is Anti-inflammatory in Human Lipopolysaccharide-Activated Monocytic Cells. Inflammation, 2015, 38, 1690-1699.	3.8	22
39	Selective activation of angiotensin <scp>AT</scp> <sub>2</sub> receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. British Journal of Pharmacology, 2015, 172, 2219-2231.	5.4	75
40	Angiotensin Type 2 Receptor Stimulation Ameliorates Left Ventricular Fibrosis and Dysfunction via Regulation of Tissue Inhibitor of Matrix Metalloproteinase 1/Matrix Metalloproteinase 9 Axis and Transforming Growth Factor β1 in the Rat Heart. Hypertension, 2014, 63, e60-7.	2.7	72
41	Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats. American Journal of Physiology - Renal Physiology, 2014, 307, F1123-F1131.	2.7	48
42	Mortality and morbidity in different immunization protocols for experimental autoimmune myocarditis in rats. Acta Physiologica, 2014, 210, 889-898.	3.8	11
43	Angiotensin Type 2 Receptor Stimulation Increases Renal Function in Female, but Not Male, Spontaneously Hypertensive Rats. Hypertension, 2014, 64, 378-383.	2.7	49
44	AT2 Receptor and Tissue Injury: Therapeutic Implications. Current Hypertension Reports, 2014, 16, 416.	3.5	101
45	AT2 Receptors Targeting Cardiac Protection Post-Myocardial Infarction. Current Hypertension Reports, 2014, 16, 441.	3.5	17
46	The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke. Neuropharmacology, 2014, 81, 134-141.	4.1	60
47	Protective arms of the renin–angiotensinâ€system in neurological disease. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 580-588.	1.9	75
48	Comment on "protective arms of the renin–angiotensin system in neurological disease― Reply. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 838-839.	1.9	2
49	AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression. Neurobiology of Disease, 2013, 51, 177-191.	4.4	81
50	Perspective: A tale of two receptors. Nature, 2013, 493, S9-S9.	27.8	16
51	Impact of AT2-receptor stimulation on vascular biology, kidney function, and blood pressure. Integrated Blood Pressure Control, 2013, 6, 153.	1.2	58
52	Direct Stimulation of Angiotensin II Type 2 Receptor Enhances Spatial Memory. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 248-255.	4.3	87
53	New therapeutic pathways in the RAS. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 505-508.	1.7	32
54	Direct Angiotensin II Type 2 Receptor Stimulation in <i>N</i> <sup>ï‰</sup> -Nitro- <scp>l</scp> -Arginine-Methyl Ester–Induced Hypertension. Hypertension, 2012, 59, 485-492.	2.7	92

#	Article	IF	CITATIONS
55	AT2 receptor agonists. Current Opinion in Nephrology and Hypertension, 2012, 21, 142-146.	2.0	86
56	Sex-Specific Influence of Angiotensin Type 2 Receptor Stimulation on Renal Function. Hypertension, 2012, 59, 409-414.	2.7	95
57	931 INHIBITION OF MICROGLIA ACTIVATION AND MIGRATION BY DIRECT AT2-RECEPTOR STIMULATION. Journal of Hypertension, 2012, 30, e269.	0.5	2
58	398 EVIDENCE OF A DIRECT MAS-AT2 RECEPTOR DIMERIZATION. Journal of Hypertension, 2012, 30, e117.	0.5	5
59	Impact of the AT2 Receptor Agonist C21 on Blood Pressure and Beyond. Current Hypertension Reports, 2012, 14, 403-409.	3.5	41
60	Angiotensin II type 2 receptor agonists – where should they be applied?. Expert Opinion on Investigational Drugs, 2012, 21, 763-766.	4.1	24
61	Direct Angiotensin II Type 2 Receptor Stimulation Ameliorates Insulin Resistance in Type 2 Diabetes Mice with PPAR <sup>13</sup> Activation. PLoS ONE, 2012, 7, e48387.	2.5	64
62	Key advances in antihypertensive treatment. Nature Reviews Cardiology, 2012, 9, 276-285.	13.7	44
63	Emerging drugs which target the renin–angiotensin–aldosterone system. Expert Opinion on Emerging Drugs, 2011, 16, 619-630.	2.4	26
64	Non-peptide AT2-receptor agonists. Current Opinion in Pharmacology, 2011, 11, 187-192.	3.5	96
65	Prevention and Intervention Studies with Telmisartan, Ramipril and Their Combination in Different Rat Stroke Models. PLoS ONE, 2011, 6, e23646.	2.5	28
66	Mast cell-derived TNF-α and histamine modify IL-6 and IL-8 expression and release from cutaneous tumor cells. Experimental Dermatology, 2011, 20, 1020-1022.	2.9	13
67	The angiotensin AT2 receptor in left ventricular hypertrophy. Journal of Hypertension, 2010, 28, S50-S55.	0.5	36
68	Ethanol-induced downregulation of the angiotensin AT2 receptor in murine fibroblasts is mediated by PARP-1. Alcohol, 2010, 44, 495-506.	1.7	10
69	The past, present and future of angiotensin II type 2 receptor stimulation. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2010, 11, 67-73.	1.7	83
70	Identification of Noncytotoxic and IL-10–Producing CD8+AT2R+ T Cell Population in Response to Ischemic Heart Injury. Journal of Immunology, 2010, 185, 6286-6293.	0.8	91
71	Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor ήB. Hypertension, 2010, 55, 924-931.	2.7	182
72	Adapter proteins and promoter regulation of the angiotensin AT2 receptor — implications for cardiac pathophysiology. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2010, 11, 7-17.	1.7	37

#	Article	IF	CITATIONS
73	The angiotensin AT2 receptor in inflammation. Drug News and Perspectives, 2010, 23, 104.	1.5	46
74	Angiotensin Receptors and Autophagy. Hypertension, 2009, 53, 898-899.	2.7	5
75	The Renin-Angiotensin System in the Eye. Frontiers in Diabetes, 2009, , 142-157.	0.4	2
76	Poly(ADP-ribose) polymerase-1 (PARP-1) transcriptionally regulates angiotensin AT2 receptor (AT2R) and AT2R binding protein (ATBP) genes. Biochemical Pharmacology, 2009, 77, 1795-1805.	4.4	29
77	Cardiac c-kit+AT2+ Cell Population is Increased in Response to Ischemic Injury and Supports Cardiomyocyte Performance. Stem Cells, 2009, 27, 2488-2497.	3.2	63
78	The evolving story of the RAAS in hypertension, diabetes and CV disease – moving from macrovascular to microvascular targets. Fundamental and Clinical Pharmacology, 2009, 23, 693-703.	1.9	75
79	Transition from atherosclerosis to aortic aneurysm in humans coincides with an increased expression of RAS components. Atherosclerosis, 2009, 205, 396-403.	0.8	50
80	The ONTARGET Trial Programme: Facts and Lessons. Current Hypertension Reviews, 2009, 5, 202-209.	0.9	0
81	Highlights from International Congress. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 91-104.	2.2	0
82	Angiotensin II Type 2 Receptor Stimulation. Circulation, 2008, 118, 2523-2532.	1.6	250
83	The β-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke. Journal of Hypertension, 2008, 26, 2426-2435.	0.5	101
84	Angiotensin in the Kidney: A Key to Understanding Hypertension?. Cell Metabolism, 2007, 5, 7-8.	16.2	6
85	Angiotensin receptor blockers and cerebral protection in stroke. Journal of Hypertension, 2006, 24, S115-S121.	O.5	53
86	Stimulation of AT2 receptors. , 2006, , 31-46.		1
87	Regulationsmechanismen des Renin-Angiotensin-Systems im kardiovaskulÄ <b>r</b> en System. , 2006, , 377-407.		0
88	Differential expression of angiotensin receptors in human cutaneous wound healing. British Journal of Dermatology, 2005, 153, 887-893.	1.5	69
89	The AT2 receptorâ $\in$ "A matter of love and hate. Peptides, 2005, 26, 1401-1409.	2.4	224
90	HYDRA: possible determinants of unsatisfactory hypertension control in German primary care patients. Blood Pressure, 2004, 13, 80-88.	1.5	26

#	Article	IF	CITATIONS
91	Human skin: source of and target organ for angiotensin II. Experimental Dermatology, 2004, 13, 148-154.	2.9	137
92	Genetic kininogen deficiency contributes to aortic aneurysm formation but not to atherosclerosis. Physiological Genomics, 2004, 19, 41-49.	2.3	35
93	Mast Cell–Fibroblast Interactions: Human Mast Cells as Source and Inducers of Fibroblast and Epithelial Growth Factors. Journal of Investigative Dermatology, 2002, 118, 391-395.	0.7	108
94	A Long-Term Coculture Model for the Study of Mast Cell–Keratinocyte Interactions. Journal of Investigative Dermatology, 2002, 119, 411-415.	0.7	21
95	Angiotensin-converting Enzyme Inhibitors as Inducers of Adverse Cutaneous Reactions. Acta Dermato-Venereologica, 2001, 81, 321-325.	1.3	71
96	Altered Expression of Mast Cell Chymase and Tryptase and of c-Kit in Human Cutaneous Scar Tissue. Journal of Investigative Dermatology, 2000, 114, 51-55.	0.7	44
97	Mast cells and their mediators in cutaneous wound healing ? active participants or innocent bystanders?. Experimental Dermatology, 1999, 8, 1-16.	2.9	226
98	Repression of c- fos and c- jun gene expression is not part of AT 2 receptor coupled signal transduction. Journal of Molecular Medicine, 1998, 76, 202-207.	3.9	16
99	The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Molecular and Cellular Endocrinology, 1996, 122, 59-67.	3.2	215
100	Angiotensin II Stimulates Proliferation of Primary Human Keratinocytes via a Non-AT1, Non-AT2Angiotensin Receptor. Biochemical and Biophysical Research Communications, 1996, 229, 329-333.	2.1	53
101	The renin-angiotensin-system in the skin. Evidence for its presence and possible functional implications. Experimental Dermatology, 1995, 4, 329-334.	2.9	11
102	The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells Journal of Clinical Investigation, 1995, 95, 651-657.	8.2	820
103	Complex Physiological and Biochemical Action of Aldosterone in Toad Urinary Bladder and Mammalian Renal Collecting Duct Cells. Kidney and Blood Pressure Research, 1987, 10, 297-310.	2.0	5
104	Methylation of cytosolic proteins may be a possible biochemical pathway of early aldosterone action in cultured renal collecting duct cells. Differentiation, 1987, 36, 23-34.	1.9	12
105	Angiotensin AT2 Receptor Stimulation Alleviates Collagen-Induced Arthritis by Upregulation of Regulatory T Cell Numbers. Frontiers in Immunology, 0, 13, .	4.8	4